Chromatin barcodes as biomarkers for melanoma

Emanuela Bastonini, Magdalena Jeznach, Megan Field, Katarzyna Juszczyk, Emily Corfield, Mehrnoush Dezfouli, Nurfilza Ahmat, Aimee Smith, Howard Womersley, Philip Jordan, Aroul Ramadass, Alexandre Akoulitchev, Colin R. Goding

Research output: Contribution to journalArticle

Abstract

The major barrier to effective cancer therapy is the presence of genetic and phenotypic heterogeneity within cancer cell populations that provides a reservoir of therapeutically resistant cells. As the degree of heterogeneity present within tumours will be proportional to tumour burden, the development of rapid, robust, accurate and sensitive biomarkers for cancer progression that could detect clinically occult disease before substantial heterogeneity develops would provide a major therapeutic benefit. Here, we explore the application of chromatin conformation capture technology to generate a diagnostic epigenetic barcode for melanoma. The results indicate that binary states from chromatin conformations at 15 loci within five genes can be used to provide rapid, non-invasive multivariate test for the presence of melanoma using as little as 200 μl of patient blood.

Original languageEnglish
Pages (from-to)788-800
Number of pages13
JournalPigment Cell and Melanoma Research
Volume27
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Biomarkers
Chromatin
Conformations
Tumors
Melanoma
Tumor Biomarkers
Neoplasms
Blood
Genetic Heterogeneity
Genes
Cells
Tumor Burden
Epigenomics
Technology
Therapeutics
Population

Keywords

  • Biomarker
  • Chromatin conformation capture
  • Epigentic
  • Melanoma

ASJC Scopus subject areas

  • Dermatology
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bastonini, E., Jeznach, M., Field, M., Juszczyk, K., Corfield, E., Dezfouli, M., ... Goding, C. R. (2014). Chromatin barcodes as biomarkers for melanoma. Pigment Cell and Melanoma Research, 27(5), 788-800. https://doi.org/10.1111/pcmr.12258

Chromatin barcodes as biomarkers for melanoma. / Bastonini, Emanuela; Jeznach, Magdalena; Field, Megan; Juszczyk, Katarzyna; Corfield, Emily; Dezfouli, Mehrnoush; Ahmat, Nurfilza; Smith, Aimee; Womersley, Howard; Jordan, Philip; Ramadass, Aroul; Akoulitchev, Alexandre; Goding, Colin R.

In: Pigment Cell and Melanoma Research, Vol. 27, No. 5, 2014, p. 788-800.

Research output: Contribution to journalArticle

Bastonini, E, Jeznach, M, Field, M, Juszczyk, K, Corfield, E, Dezfouli, M, Ahmat, N, Smith, A, Womersley, H, Jordan, P, Ramadass, A, Akoulitchev, A & Goding, CR 2014, 'Chromatin barcodes as biomarkers for melanoma', Pigment Cell and Melanoma Research, vol. 27, no. 5, pp. 788-800. https://doi.org/10.1111/pcmr.12258
Bastonini E, Jeznach M, Field M, Juszczyk K, Corfield E, Dezfouli M et al. Chromatin barcodes as biomarkers for melanoma. Pigment Cell and Melanoma Research. 2014;27(5):788-800. https://doi.org/10.1111/pcmr.12258
Bastonini, Emanuela ; Jeznach, Magdalena ; Field, Megan ; Juszczyk, Katarzyna ; Corfield, Emily ; Dezfouli, Mehrnoush ; Ahmat, Nurfilza ; Smith, Aimee ; Womersley, Howard ; Jordan, Philip ; Ramadass, Aroul ; Akoulitchev, Alexandre ; Goding, Colin R. / Chromatin barcodes as biomarkers for melanoma. In: Pigment Cell and Melanoma Research. 2014 ; Vol. 27, No. 5. pp. 788-800.
@article{d97d9482e4504f288472132bcbc1ed7f,
title = "Chromatin barcodes as biomarkers for melanoma",
abstract = "The major barrier to effective cancer therapy is the presence of genetic and phenotypic heterogeneity within cancer cell populations that provides a reservoir of therapeutically resistant cells. As the degree of heterogeneity present within tumours will be proportional to tumour burden, the development of rapid, robust, accurate and sensitive biomarkers for cancer progression that could detect clinically occult disease before substantial heterogeneity develops would provide a major therapeutic benefit. Here, we explore the application of chromatin conformation capture technology to generate a diagnostic epigenetic barcode for melanoma. The results indicate that binary states from chromatin conformations at 15 loci within five genes can be used to provide rapid, non-invasive multivariate test for the presence of melanoma using as little as 200 μl of patient blood.",
keywords = "Biomarker, Chromatin conformation capture, Epigentic, Melanoma",
author = "Emanuela Bastonini and Magdalena Jeznach and Megan Field and Katarzyna Juszczyk and Emily Corfield and Mehrnoush Dezfouli and Nurfilza Ahmat and Aimee Smith and Howard Womersley and Philip Jordan and Aroul Ramadass and Alexandre Akoulitchev and Goding, {Colin R.}",
year = "2014",
doi = "10.1111/pcmr.12258",
language = "English",
volume = "27",
pages = "788--800",
journal = "Pigment Cell and Melanoma Research",
issn = "1755-1471",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Chromatin barcodes as biomarkers for melanoma

AU - Bastonini, Emanuela

AU - Jeznach, Magdalena

AU - Field, Megan

AU - Juszczyk, Katarzyna

AU - Corfield, Emily

AU - Dezfouli, Mehrnoush

AU - Ahmat, Nurfilza

AU - Smith, Aimee

AU - Womersley, Howard

AU - Jordan, Philip

AU - Ramadass, Aroul

AU - Akoulitchev, Alexandre

AU - Goding, Colin R.

PY - 2014

Y1 - 2014

N2 - The major barrier to effective cancer therapy is the presence of genetic and phenotypic heterogeneity within cancer cell populations that provides a reservoir of therapeutically resistant cells. As the degree of heterogeneity present within tumours will be proportional to tumour burden, the development of rapid, robust, accurate and sensitive biomarkers for cancer progression that could detect clinically occult disease before substantial heterogeneity develops would provide a major therapeutic benefit. Here, we explore the application of chromatin conformation capture technology to generate a diagnostic epigenetic barcode for melanoma. The results indicate that binary states from chromatin conformations at 15 loci within five genes can be used to provide rapid, non-invasive multivariate test for the presence of melanoma using as little as 200 μl of patient blood.

AB - The major barrier to effective cancer therapy is the presence of genetic and phenotypic heterogeneity within cancer cell populations that provides a reservoir of therapeutically resistant cells. As the degree of heterogeneity present within tumours will be proportional to tumour burden, the development of rapid, robust, accurate and sensitive biomarkers for cancer progression that could detect clinically occult disease before substantial heterogeneity develops would provide a major therapeutic benefit. Here, we explore the application of chromatin conformation capture technology to generate a diagnostic epigenetic barcode for melanoma. The results indicate that binary states from chromatin conformations at 15 loci within five genes can be used to provide rapid, non-invasive multivariate test for the presence of melanoma using as little as 200 μl of patient blood.

KW - Biomarker

KW - Chromatin conformation capture

KW - Epigentic

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84906809675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906809675&partnerID=8YFLogxK

U2 - 10.1111/pcmr.12258

DO - 10.1111/pcmr.12258

M3 - Article

C2 - 24807349

AN - SCOPUS:84906809675

VL - 27

SP - 788

EP - 800

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

SN - 1755-1471

IS - 5

ER -